Elmind Capital LP Makes New Investment in Celldex Therapeutics, Inc. $CLDX

Elmind Capital LP bought a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the 4th quarter, Holdings Channel.com reports. The institutional investor bought 865,000 shares of the biopharmaceutical company’s stock, valued at approximately $23,493,000. Celldex Therapeutics accounts for about 6.9% of Elmind Capital LP’s portfolio, making the stock its 5th biggest holding.

Several other large investors also recently bought and sold shares of CLDX. Aster Capital Management DIFC Ltd acquired a new stake in Celldex Therapeutics in the third quarter valued at $26,000. Wilmington Savings Fund Society FSB purchased a new position in shares of Celldex Therapeutics in the 3rd quarter worth about $42,000. Russell Investments Group Ltd. raised its holdings in shares of Celldex Therapeutics by 27.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 501 shares during the period. Quantbot Technologies LP purchased a new position in shares of Celldex Therapeutics in the 3rd quarter worth about $63,000. Finally, Kestra Advisory Services LLC purchased a new position in shares of Celldex Therapeutics in the 4th quarter worth about $98,000.

Celldex Therapeutics Stock Performance

Shares of CLDX stock opened at $32.93 on Thursday. Celldex Therapeutics, Inc. has a 1 year low of $19.52 and a 1 year high of $35.79. The stock has a fifty day moving average of $31.96 and a two-hundred day moving average of $28.97. The firm has a market capitalization of $2.58 billion, a PE ratio of -7.73 and a beta of 0.95.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.03). The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.80 million. Equities research analysts predict that Celldex Therapeutics, Inc. will post -4.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Wolfe Research raised Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 price target on the stock in a research report on Monday, March 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Monday, April 20th. HC Wainwright restated a “buy” rating and set a $42.00 price objective on shares of Celldex Therapeutics in a report on Monday. Stifel Nicolaus reiterated a “buy” rating and issued a $68.00 price target (up from $58.00) on shares of Celldex Therapeutics in a report on Thursday, February 26th. Finally, Wall Street Zen upgraded Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $49.30.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.